September 2024 – Insights Care recently interviewed Nusano CEO Chris Lowe for its “5 Most Trusted Radiopharmaceutical Companies to Watch” edition.
Lowe discussed the urgent need for new medical radioisotope supplies, how Nusano will be part of the solution, and his advice for young professionals entering the radiopharmaceuticals industry.
Lowe said:
“Our biggest challenge and our biggest enemy is time. Today, drug development is constrained by limited isotope availability. The sooner Nusano – and others – bring new isotope supplies to market, the sooner patients will be able to get the therapies they need, and the sooner development can begin on the next wave of radiopharmaceuticals. The clinical evidence is compelling that these therapies can help a large number of patients.”
The full interview is available on Insights Care‘s website.
